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Abstract
Background: A number of recent studies have suggested that cancer incidence rates may be
lower in patients receiving statin treatment for hypercholesterolemia. We examined the effects of
statin drugs on in vitro proliferation, migration and invasion of melanoma cells.
Methods:  The ability of lovastatin, mevastatin and simvastatin to inhibit the melanoma cell
proliferation was examined using cytotoxicity and apoptosis assays. Effects on cell migration and
invasion were assessed using transwell invasion and migration chambers. Hypothesis testing was
performed using 1-way ANOVA, and Student's t-test.
Results: Lovastatin, mevastatin and simvastatin inhibited the growth, cell migration and invasion of
HT144, M14 and SK-MEL-28 melanoma cells. The concentrations required to inhibit proliferation
of melanoma cells (0.8–2.1 μM) have previously been achieved in a phase I clinical trial of lovastatin
in patients with solid tumours, (45 mg/kg/day resulted in peak plasma concentrations of
approximately 3.9 μM).
Conclusion:  Our results suggest that statin treatment is unlikely to prevent melanoma
development at standard doses. However, higher doses of statins may have a role to play in
adjuvant therapy by inhibiting growth and invasion of melanoma cells.
Background
The statins are group of drugs routinely used in the treat-
ment of lipid disorders, including hypercholesterolemia.
Statins exert their effects through the inhibition of 3-
hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-
CoA reductase). HMG-CoA reductase catalyses the conver-
sion of HMG-CoA into mevalonate in the mevalonate
biosynthetic pathway [1,2].
In addition to the cholesterol lowering effects of statins, a
number of recent studies suggest that the cancer incidence
rates may be lower in patients receiving statins. The Air
Force/Texas Coronary Atherosclerosis Prevention Study
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(AFCAPS/TexCAPS) trial to evaluate the efficacy of lovas-
tatin for preventing coronary events, found a significantly
decreased incidence of new melanomas in the lovastatin
arm compared with the placebo arm. In addition, among
the 41 participants who developed melanoma, there was
a trend, although not statistically significant, toward ear-
lier stage at diagnosis in the lovastatin group [3]. A recent
meta-analysis described the incidence of melanoma in 12
qualifying randomized controlled statin trials, with a total
of 39,426 participants. They reported that a total of 127
melanomas occurred, 59 among the 19,872 statin group
participants and 68 among the 19,554 control group par-
ticipants. The reported odds ratio for melanoma was in
the direction of a protective effect, but did not reach sig-
nificance (OR = 0.87, 95% CI = 0.61 to 1.23). As the
number of incident melanoma cases was low, a specific
study to address the role of statins in preventing
melanoma needs to be designed, with the required power
to provide answers [4].
Lung cancer incidences rates in statin users were found to
be significantly reduced (55% risk reduction) in the Veter-
ans Affairs (VA) Health Care System case control study [5].
Several studies have also suggested that colorectal cancer
rates are reduced amongst statin users, including the
Molecular Epidemiology of Colorectal Cancer study [6],
and in the Rhine-Neckar-Odenwald population case-con-
trol study [7]. Graaf et al [8] also reported that statin use
was associated with a risk reduction of cancer of 20%
(adjusted odds ratio [OR], 0.80; 95% CI, 0.66 to 0.96).
However, other studies have shown no benefit for statin
use with respect to cancer prevention. Jacob et al [9] exam-
ined the association between use of cholesterol-lowering
drugs and colorectal cancer incidence among 132,136
men and women in the Cancer Prevention Study II Nutri-
tion Cohort. Current or 5 year use of cholesterol-lowering
drugs was not associated with colorectal cancer incidence.
A recent meta-analysis study including 6662 incident can-
cers and 2407 cancer deaths showed that statins did not
reduce the incidence of cancer (OR, 1.02; 95% CI,
0.97–1.07) or cancer deaths (OR, 1.01; 95% CI,
0.93–1.09) and there was no reduction in any individual
cancer type [10]. These conflicting reports highlight the
need for further studies on the effects of statins on cancer
cells.
A number of studies have investigated the effects of statins
on melanoma cells. Lovastatin induces apoptosis in A375
melanoma cells [11] and also enhances response to chem-
otherapy drugs in the B16 mouse model of melanoma
[12,13]. Collisson et al [14] showed that atorvastatin
inhibited in vitro invasion and in vivo metastasis of A375M
melanoma cells. Depasquale and Wheatley [15] recently
showed that lovastatin reduced both melanoma cell
growth and angiogenesis in an in vitro co-culture model
angiogenesis system. These studies support the hypothesis
that statins may play a role in melanoma prevention or
treatment. However, the conflicting evidence from the
chemoprevention studies suggests that further investiga-
tion is required to determine if standard choletsterol-low-
ering doses of statins will inhibit the growth of melanoma
cells.
In this study we compared sensitivity to simvastatin, lov-
astatin and mevastatin across a panel of melanoma, lung
and breast cancer cell lines and systematically examined
the effects of the statins on apoptosis, adhesion, motility
and invasion in melanoma cells.
Methods
Chemicals
Pravastatin sodium, mevastatin sodium, lovastatin
sodium and simvastatin sodium (activated forms) were
obtained from Merck Biosciences Ltd (Nottingham, UK)
and reconstituted in DMSO. All media, serum and other
chemicals were obtained from Sigma (Dublin, Ireland),
unless otherwise stated.
Cell lines
DLRP and MCF-7 were cultured in ATCC media supple-
mented with 2 mM L-glutamine (Gibco) and 10% foetal
calf serum. SK-MEL-28, M14, HT144, SKBR-3 and MDA-
MB-453 were cultured in RPMI 1640 media supple-
mented with 2 mM L-glutamine (Gibco) and 10% foetal
calf serum. The melanoma cell lines, SK-MEL-28 and M14
were obtained from the Division of Cancer Treatment and
Diagnosis Tumor Repository, NCI. H1299 was cultured in
RPMI 1640 media supplemented with 5% foetal calf
serum. BT474A, a clonal population of BT474, was cul-
tured in RPMI 1640 media supplemented with 4 mM L-
glutamine (Gibco), 0.1 mg/ml bovine insulin and 10%
foetal calf serum. Cells were maintained at 37°C. Antibi-
otics were not used in the growth media. All cell lines were
free from mycoplasma as tested with the indirect Hoechst
DNA staining method.
Cytotoxicity assays
Sensitivity to pravastatin sodium, mevastatin sodium, lov-
astatin sodium and simvastatin sodium in the panel of
cell lines was determined by the acid phosphatase
method, which measures viable cell number after 6 days
of continuous exposure to drugs as previously described
[16]. Toxicity assays were performed on at least two sepa-
rate occasions, in triplicate (3 individual 96 well plates)
for each cell line for each drug. Eight replicate wells, on
the 96 well plate were used per drug concentration.
Apoptosis assay
The ability of the statins to induce apoptosis was assessed
in M14 cells using the Guava Nexin kit (Guava Technolo-BMC Cancer 2008, 8:9 http://www.biomedcentral.com/1471-2407/8/9
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gies, Hayward, CA). Briefly, 2.5 × 105 cells were plated per
well in 24 well plates and incubated overnight to allow
attachment. Cells were treated with lovastatin, mevastatin
or simvastatin (4 and 8 μM) for 72 hours. 0.1 μM taxol
was used as a control for induction of apoptosis. After 72
hours apoptotic cells in the medium were collected and
adherent cells were trypsinized. The resulting pool of cells
was centrifuged at 300×g for 5 minutes, then resuspended
in 50 μl of fresh medium and transferred to a round-bot-
tom 96 well plate (Costar). 150 μl of Nexin Working Rea-
gent (10 μl Annexin V-PE, 5 μl Nexin 7-AAD and 135 μl
1× Nexin buffer) was added to each well and the plate was
incubated protected from light for 20 minutes at room
temperature. After incubation the samples were acquired
on the Guava EasyCyte. The Annexin V-PE detects phos-
phatidyl-serine on the external membrane of apoptotic
cells and 7-AAD, a cell impermeant dye, is an indicator of
membrane structural integrity. 7-AAD is excluded from
live, healthy cells and early apoptotic cells, but permeates
late-stage apoptotic and dead cells. Cells which stain pos-
itive for Annexin V-PE and negative for 7-AAD are classi-
fied as early apoptotic cells, whilst cells which are positive
for both represent late apoptotic cells.
Invasion assays and motility assays
Invasion assays were performed by a modification of the
method described by Albini et al [17,18]. Matrigel
(Sigma) was diluted to 1 mg/ml in serum-free DMEM
medium. 100 μl of 1 mg/ml matrigel was placed into each
insert (Falcon) (8.0 mm pore size), in a 24-well plate
(Costar). The inserts were incubated at 37°C for 1 hour to
allow gel polymerisation. Cells were harvested and sus-
pended in DMEM containing 10% FCS at a concentration
of 1 × 106 cells/ml. The inserts were washed with the
appropriate serum-free medium, then 100 μl of the cell
suspension and 100 μl of statin at 2× concentration was
added to each insert and 500 μl of appropriate medium
containing 10% FCS was added to the well underneath
the insert. Cells were incubated at 37°C for 24 hours. After
this time, the inner side of the insert was wiped with a wet
swab to remove the cells while the outer side of the insert
was gently rinsed with PBS and stained with 0.25% crystal
violet for 10 min, rinsed again and then allowed to dry.
The inserts were then viewed under the microscope and
the number of cells per field in 10 random fields, were
counted at 200× magnification. The average number of
cells per field was then multiplied by a factor of 140
(growth area of membrane/field area viewed at 200× mag-
nification (calibrated using a microscope graticule)) to
determine the total number of invading/migrating cells.
The procedure for carrying out motility assays was identi-
cal to the procedure used for invasion assays with the
exception that the inserts were not coated with matrigel.
Integrin-mediated binding assays
Integrin mediated adhesion was examined using the α/β
Integrin-mediated cell adhesion array combo kits
(Chemicon, UK). These kits use mouse monoclonal anti-
bodies generated against human alpha (α1, α2, α3, α4,
α5, αV, and αvβ3), and beta (β1, β2, β3, β4, β6, αVβ5,
and α5β1) integrins/subunits, that are immobilized onto
a goat anti-mouse antibody coated micro-titre plate. The
plate is then used to capture cells expressing these
integrins on their cell surface. The strips were re-hydrated
with 200 μL of PBS per well for 10 min at room tempera-
ture. The plate was tapped on tissue paper to remove PBS.
SK-MEL-28 and HT144 cells were incubated in the pres-
ence or absence of 0.8 μM simvastatin for 24 hours. Cells
were harvested and plated at 1 × 105 cells per well in trip-
licate in serum free culture medium and incubated at
37°C for 1 hour. Medium and unbound cells were
removed from the wells and rinsed gently twice with 200
μl assay buffer. 100 μl of cell stain solution was added to
each well and incubated for 5 minutes at room tempera-
ture. The plates were washed 3 times with de-ionized
water and allowed to air dry. 100 μL of Extraction Buffer
was added to each well and the plate read in an ELISA
reader at 560 nm.
Extracellular matrix (ECM) protein binding assays
Adhesion assays were performed on CytoMatrix™ screen-
ing kits (Chemicon, UK). 96-well plates pre-coated indi-
vidually with fibronectin, vitronectin, laminin, collagen I
or collagen IV were re-hydrated with 200 μL of PBS per
well for 15 min at room temperature, then the PBS was
removed. A control non-coated plate was included. SK-
MEL-28 and HT144 cells were incubated in the presence
or absence of 0.8 μM simvastatin for 24 hours. Cells were
harvested and plated at 1 × 105 cells per well (replicates of
seven) in serum free culture medium and incubated at
37°C for 1 hour. Medium and unbound cells were
removed from the wells and rinsed gently with PBS. 100
μl of freshly prepared phosphatase substrate (10 mM p-
nitrophenol phosphate in 0.1 M sodium acetate, 0.1% tri-
ton ×-100, pH 5.5) was added to each well. The plates
were then incubated in the dark at 37°C for 2 h. The enzy-
matic reaction was stopped by the addition of 50 μl of 1
N NaOH. The optical density was determined at a wave-
length of 405 nm, with a reference wavelength of 620 nm.
The optical density at 620 nm was subtracted from that at
405 nm to give the appropriate optical density of each
sample.
Statistical analysis
Statistical analyses were performed using Stata Inter-
cooled 9.0 and GraphPad Prism Version 4. A p-value <
0.05 was deemed significant. A p-value < 0.005 was
deemed highly significant.BMC Cancer 2008, 8:9 http://www.biomedcentral.com/1471-2407/8/9
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Results
Lung cancer and melanoma cell lines are sensitive to 
statins, while breast cancer cell lines are resistant
As statins have been proposed as chemoprevention agents
for a variety of cancer types including lung cancer, breast
cancer and melanoma, we tested a range of cancer cell
lines for sensitivity to four statin drugs, simvastatin, lovas-
tatin, mevastatin and pravastatin. Pravastatin failed to
inhibit proliferation (data not shown). Of the three
remaining drugs, simvastatin displayed the greatest
potency, followed by lovastatin and finally mevastatin
(Table 1). The cell lines were derived from lung carcino-
mas (H1299, DLRP), breast carcinomas (MCF-7, BT474A,
MDA-MB-453, SKBR-3) and malignant melanomas
(HT144, M14, SK-MEL-28). There was a statistically signif-
icant difference in statin resistance across all the groups
(one-way Anova: p = 0.011 [lovastatin]; p = 0.028 [mevas-
tatin]; p = 0.013 [simvastatin]), demonstrating variance in
resistance to statins by cancer site. Further analysis
showed that the breast cancer cell lines were more resist-
ant to statins, when compared to the lung cancer and
melanoma cell lines (2-sided unpaired Student's t-test, p
= 0.002 (lovastatin), p = 0.025 (mevastatin), p = 0.016
(simvastatin)). The melanoma cell lines displayed the
greatest sensitivity to the statins, although not statistically
significantly lower than the lung cancer cell lines.
Statins induce apoptosis in M14 melanoma cells
To determine if the effects of the statins on proliferation
were due to cytostatic or cytocidal effects on the
melanoma cells we examined the ability of statins to
induce apoptosis in the M14 cell line. M14 cells were
exposed to two doses (4 and 8 μM) of lovastatin, mevas-
tatin and simvastatin over 72 hours. Following statin
exposure, the percentage of apoptotic cells was deter-
mined using an annexin V assay on the Guava EasyCyte.
Apoptosis was increased in a dose-dependant manner in
response to all three statins (Figure 1). Regression analysis
shows that there is a significant trend toward increased
levels of late apoptosis and total apoptosis with increasing
statin concentration (Linear regression: p = 0.012 (r =
0.79) and p = 0.019 (r = 0.75) (late and total apoptosis for
lovastatin), p = 0.003 (r = 0.86) and p = 0.044 (r = 0.46)
(late and total apoptosis for mevastatin), p = 0.014 (r =
0.77) and p = 0.038 (r = 0.69) (late and total apoptosis for
simvastatin)). No significant trend was observed for early
apoptosis.
Effect of simvastatin, lovastatin and mevastatin on 
melanoma cell migration and invasion
The effects of the statins on cell migration and invasion
were examined in three melanoma cell lines (M14, HT144
and SK-MEL-28), which were more sensitive to the statins
than the lung and breast cancer cell lines. The three
melanoma cell lines were both invasive and motile to var-
ying degrees (Figure 2).
To assess whether statins can inhibit melanoma cell inva-
sion, cells were exposed to escalating doses of statin drugs
over 24 hours in invasion assays. Growth assays were also
performed with these concentrations to ensure that they
were non-toxic over the course of the assays. Each of the
statin drugs had an inhibitory effect, on invasion, in a
dose dependant manner on all three melanoma cell lines
(Figure 3A–C). Regression analysis showed a significant
trend toward decreased levels of cell invasion with
increasing statin concentration in SK-MEL-28 cells (Linear
regression: p < 0.001 (lovastatin), p = 0.001 (mevastatin),
p < 0.001 (simvastatin)), HT144 cells (Linear regression:
p < 0.001 (lovastatin), p < 0.001 (mevastatin), p < 0.001
(simvastatin)), and in M14 cells with the exception of lov-
astatin (Linear regression: p = 0.073 (lovastatin), p <
0.001 (mevastatin), p = 0.003 (simvastatin)). The effects
of statins on cell migration were also examined by expo-
sure of cells in migration assays and the statins inhibited
migration in the three melanoma cell lines, with the
exception of simvastatin in M14 cells (Figure 3D).
Table 1: IC50 values for lovastatin, mevastatin and simvastatin (± std. deviation)
Cell Line IC50 Lovastatin (μM) IC50 Mevastatin (μM) IC50 Simvastatin (μM)
Lung cancer
DLRP 1.7 ± 0.5 1.9 ± 0.1 0.9 ± 0.1
H1299 2.6 ± 0.4 5.1 ± 0.3 1.3 ± 0.2
Melanoma
HT144 1.7 ± 0.12 2.0 ± 0.33 1.0 ± 0.10
M14 1.2 ± 0.05 1.9 ± 0.10 0.8 ± 0.05
SK-MEL-28 1.3 ± 0.15 2.1 ± 0.11 0.8 ± 0.11
Breast cancer
BT474A 5.3 ± 0.8 11.1 ± 1.5 4.2 ± 1.8
SKBR-3 4.7 ± 1.6 4.3 ± 0.6 2.2 ± 0.3
MDA-MB-453 7.8 ± 1.2 12.2 ± 3.5 5.4 ± 1.0
BT-20 3.9 ± 2.5 4.8 ± 1.6 1.7 ± 0.7BMC Cancer 2008, 8:9 http://www.biomedcentral.com/1471-2407/8/9
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Effect of simvastatin, lovastatin and mevastatin on 
adhesion
SK-MEL-28 and HT144 melanoma cells were treated with
0.8 μM simvastatin for 24 hours to study the effect of sim-
vastatin on adhesion to the ECM proteins, fibronectin,
laminin, collagen type I, vitronectin and collagen type IV.
Simvastatin exposure resulted in significantly decreased
adhesion to laminin and collagen type IV in both cell
lines, while collagen type I and vitronectin adhesion was
only significantly decreased in HT144 cells (Figure 4).
SK-MEL-28 and HT144 melanoma cells were treated with
0.8 μM simvastatin for 24 hours to study the effect of sim-
vastatin on alpha and beta integrin mediated binding.
HT144 displayed significantly decreased alpha 4 and
alpha v beta 5 integrin-mediated binding (Figure 5). SK-
MEL-28 did not display any significant changes in
integrin-mediated binding.
Discussion
We hypothesized that the statin drugs, simvastatin, lovas-
tatin, mevastatin and pravastatin would have inhibitory
effects on melanoma cell proliferation, invasion and cell
migration in vitro. First we examined the effects of the
drugs on cell proliferation in three melanoma, two lung
cancer and four breast cancer cell lines. The lipophilic stat-
ins, simvastatin, lovastatin and mevastatin inhibited the
proliferation of all cell lines tested, while pravastatin, a
non-lipophilic statin, did not significantly inhibit prolif-
eration of any of the cell lines tested. This supports previ-
ous findings [19,20] and may be explained by the fact that
unlike the lipophilic statins, a sodium-independent bile
acid transporter mediates uptake of pravastatin by cells,
which is absent on most extra-hepatic cells [21]. A signif-
icant difference was found in the sensitivity of the
melanoma and lung cancer cell lines to statins compared
to the breast cancer cell lines in this study. The literature
supports these findings, as epidemiological studies have
failed to find a link between statin use and breast cancer
incidence. Bonovas et al [22] performed a meta-analysis of
seven large randomised trials and nine observational
studies (five case-control and four cohort studies) on
breast cancer risk and statin use. Statin use was not found
to significantly affect breast cancer risk (fixed effects
model: RR = 1.03; 95% CI, 0.93 to 1.14; random effects
model: RR = 1.02; 95% CI, 0.89 to 1.18). In addition, Eli-
assen et al [23] retrospectively looked at the associations
of statin use and breast cancer risk in the Nurses' Health
Study (n = 75,828), with 6 to 12 years of follow-up. 3177
incident cases of invasive breast cancer were documented,
but were not associated with statin use (RR, 0.91; 95% CI,
0.76–1.08). A similar lack of association was reported in a
recent population based study [24]. These results suggest
that statins do not affect the pathology of breast cancer,
which may correlate at least in part with our results which
show that breast cancer cells are relatively insensitive to
statins.
Our findings suggested that melanoma may be sensitive
to statin treatment. To further investigate this finding, we
examined the effects of statins on melanoma cell apopto-
Comparison of invasion and migration potential of three  melanoma cell lines Figure 2
Comparison of invasion and migration potential of three 
melanoma cell lines. 1 × 105 cells were seeded in matrigel 
coated chambers for invasion assays and uncoated chambers 
for migration assays. Error bars represent the standard error 
of the mean for triplicate experiments. * indicates p < 0.05 
and ** indicates p < 0.005 using the Student's t-test to com-
pare levels of invasion and migration between cell lines.
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Induction of apoptosis in M14 melanoma cells by statins Figure 1
Induction of apoptosis in M14 melanoma cells by statins. M14 
cells were exposed to statin treatment for 72 hours. Taxol 
(0.1 μM) was used as a positive control for apoptosis induc-
tion. Apoptosis was measured using an annexin V assay on 
the Guava EasyCyte, and results presented as % early and 
late apoptotic cells. (Lova = Lovastatin, Meva = Mevastatin, 
Simva = Simvastatin). Error bars represent std error of the 
mean for triplicate experiments. * indicates p < 0.05 using 
the Student's t-test to compare levels of late apoptosis in sta-
tin treated cells versus control.
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sis using the M14 melanoma cell line. Lovastatin, mevas-
tatin and simvastatin increased the percentage of
apoptotic cells in a dose-dependant manner. However,
the concentrations which induced apoptosis in the M14
cells were significantly higher than the IC50 concentra-
tions determined in the proliferation assays. Although the
duration of the assays are different, it is probable that the
statins have both cytocidal and cytostatic effects in
melanoma cells. Lovastatin has previously been reported
to induce apoptosis and cell cycle arrest in melanoma cell
lines [11,25].
Due to the highly metastatic nature of melanoma, we
wanted to determine whether the statin drugs were capa-
ble of inhibiting melanoma cell migration and/or inva-
sion. Lovastatin, mevastatin and simvastatin were found
to inhibit melanoma cell invasion in vitro in all three
melanoma cell lines at non-toxic concentrations, in a dose
dependant manner. Similar findings were observed in cell
migration assays, with the exception of simvastatin in one
of the cell lines. These results indicate a dual role for stat-
ins in the treatment or prevention of melanoma. Collis-
son et al [14] described atorvastatin inhibition of invasion
of the melanoma cell lines A375M, CHL, SK-MEL-28, and
WM 166-4 in a dose dependant manner, with A375M
invasion being inhibited at non-toxic concentrations.
Farina et al [26] described the metastatic inhibition of
F311 mammary carcinoma cells in BALB/c mice following
pre-treatment with a non-cytotoxic concentration of lov-
astatin.
To further investigate possible mechanisms through
which statins may exert their inhibitory effects on inva-
sion and migration of melanoma cells, we examined the
Effects of (A) lovastatin, (B) mevastatin and (C) simvastatin on invasion and (D) migration of melanoma cell lines Figure 3
Effects of (A) lovastatin, (B) mevastatin and (C) simvastatin on invasion and (D) migration of melanoma cell lines. 1 × 105 cells 
were seeded for each assay. Error bars represent the standard error of the mean for at least 4 assays. * indicates p < 0.05 using 
the Student's t-test to compare invasion levels of statin treated cells versus control.
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effects of simvastatin on the ability of HT144 and SK-
MEL-28 to adhere to extracellular matrix proteins. Small
changes in adhesion to a number of extracellular matrix
proteins were observed. Simvastatin decreased the ability
of the cells to adhere to laminin and collagen type IV in
both cell lines. Laminin and collagen type IV are impor-
tant components of the extracellular matrix, and play a
role in cell adhesion and motility. Laminin also plays a
major role in the remodelling of the melanoma microen-
vironment, and is required for melanoma vasculogenic
mimicry and activation of integrin signalling [27]. Colla-
gen type IV is a regulator of melanoma cell adhesion, pro-
liferation, cell migration and invasion and melanoma
induced angiogenesis [28]. Properties distinguishing
metastasising and non-metastasising melanoma cells
have been described, including an increased capacity for
laminin and collagen binding [29]. Thus the inhibition of
laminin and collagen type IV cell adhesion by simvastatin,
may contribute to its anti-invasive effects.
As extracellular matrix protein adhesion is mediated by
integrins we then examined the effects of simvastatin
treatment on integrin binding in the melanoma cells.
Small changes in integrin binding were also observed but
simvastatin treatment significantly decreased the binding
of alpha 4 and alpha v beta 5 integrins in HT144 cells, and
not in SK-MEL-28. Alpha v beta 5 integrin has been shown
to mediate melanoma cell vitronectin binding [30], which
is consistent with our findings that simvastatin treatment
significantly decreased adhesion of HT144 cells to vit-
ronectin. CNTO 95, an alpha v integrin humanised mon-
oclonal antibody, also inhibits human melanoma cell
adhesion, migration and invasion [31]. Alterations in
expression of matrix-metalloproteases and cytoskeletal
reorganization may also contribute to the effects of the
statins on invasion and migration of melanoma cells.
The peak plasma concentration of simvastatin achieved in
patients receiving a 40 mg per day dose is approximately
3 ng/ml (7.2 nM) [32]. However, a recent dose finding
study in patients with myeloma or lymphoma found that
the maximum tolerated dose of simvastatin, given in com-
bination with chemotherapy, was 15 mg/kg/day [33],
which suggests that much higher plasma concentrations
could be achieved. In a Phase I clinical trial in patients
with solid tumours, lovastatin administered at 45 mg/kg/
day resulted in peak plasma concentrations of approxi-
mately 3.9 μM [34], which is higher than the concentra-
tions required to inhibit proliferation and invasion of
melanoma cells in vitro.
Conclusion
Our results suggest that the standard doses used for cho-
lesterol treatment may not be sufficient to directly inhibit
melanoma cell proliferation or invasion. Therefore, stat-
ins are unlikely to be beneficial for chemoprevention of
melanoma. However, statin treatment at higher doses
may be beneficial as an adjuvant therapy to inhibit
melanoma cell growth, invasion and metastasis. A trial is
currently open to examine the effects of lovastatin in treat-
ing patients at high risk of recurrent melanoma
(NCT00462280 [35]). Synergistic interactions have been
(A) α-Integrin and (B) β-integrin mediated binding profile of  untreated HT144, HT144 treated with 0.8 μM simvastatin,  SK-MEL-28 untreated and SK-MEL-28 treated with 0.8 μM  simvastatin Figure 5
(A) α-Integrin and (B) β-integrin mediated binding profile of 
untreated HT144, HT144 treated with 0.8 μM simvastatin, 
SK-MEL-28 untreated and SK-MEL-28 treated with 0.8 μM 
simvastatin. * indicates p < 0.05 using the Student's t-test.
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observed between statins and several chemotherapy
agents in vitro [36]. Therefore, it is likely that the greatest
potential for statins in melanoma treatment would be in
combination with chemotherapy or with emerging tar-
geted therapies. Further research is required to examine
whether statins can act either additively or synergistically
in combination with chemotherapeutics to increase cell
kill, and whether these effects are reversible with the addi-
tion of mevalonic acid. Combinations of statins with
chemotherapy should first be tested in vitro and then pro-
ceed to in vivo animal studies to examine effects on
tumour burden and/or tumour invasion and metastatic
spread, prior to initiation of clinical trials examining the
addition of high dose statins to chemotherapy in humans.
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